Hims & Hers Health (NYSE:HIMS) Insider Deborah Autor Sells 16,773 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) insider Deborah Autor sold 16,773 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total value of $467,128.05. Following the completion of the transaction, the insider owned 48,961 shares of the company’s stock, valued at $1,363,563.85. This trade represents a 25.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Trading Up 2.8%

HIMS traded up $0.86 during trading on Thursday, reaching $31.95. The company had a trading volume of 18,861,192 shares, compared to its average volume of 26,241,924. The firm’s 50-day simple moving average is $32.17 and its 200 day simple moving average is $26.05. The company has a market cap of $7.45 billion, a price-to-earnings ratio of -50.71 and a beta of 2.40. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $65.30. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same period in the prior year, the company posted $0.17 earnings per share. Hims & Hers Health’s quarterly revenue was up 38.2% compared to the same quarter last year. Equities research analysts anticipate that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current year.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum rejected the FTC’s allegations concerning data privacy, advertising, billing and subscription cancellations, arguing that the agency misunderstands Hims & Hers’ business practices. His comments may be helping ease concerns after the recent regulatory-driven selloff. Hims & Hers rejects privacy allegations
• Positive Sentiment: Analysts remain focused on Hims & Hers’ growth potential, including margin expansion and broader access to care. A recent investment thesis characterized the current margin pressure as a potential buying opportunity, while the CEO said an AI health coach could launch within roughly 12 months and potentially improve medication adherence. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Management’s planned expansion into AI-enabled care, testosterone and peptide treatments could create new growth avenues, but these initiatives remain prospective and do not immediately resolve regulatory or profitability concerns.
• Negative Sentiment: The FTC lawsuit remains the central overhang. It alleges improper handling of private health data and potentially deceptive billing and cancellation practices. Multiple law firms, including Kaplan Fox, Berger Montague and Kessler Topaz, have announced investigations that could increase legal costs, compliance requirements and potential securities-liability exposure. Kaplan Fox investigation
• Negative Sentiment: Recent earnings showed strong revenue growth of 38.2% year over year and revenue above expectations, but the company posted a substantially larger-than-expected loss. The $0.37 adjusted loss per share versus a $0.05 consensus loss highlights investor concerns about margins and execution.
• Negative Sentiment: Several executives reported stock dispositions, including sales by the CEO, CFO and CTO. Most were nondiscretionary share withholdings or sales under Rule 10b5-1 plans to cover taxes on vested equity, limiting their value as a confidence signal but still adding a modest supply-related overhang. SEC insider transaction filing

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Hims & Hers Health by 23.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock worth $12,373,000 after buying an additional 78,543 shares in the last quarter. Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health during the 1st quarter valued at $30,000. EverSource Wealth Advisors LLC increased its stake in shares of Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after acquiring an additional 687 shares during the last quarter. Amundi raised its holdings in shares of Hims & Hers Health by 5.3% during the second quarter. Amundi now owns 10,296 shares of the company’s stock worth $489,000 after acquiring an additional 522 shares in the last quarter. Finally, California Public Employees Retirement System boosted its position in Hims & Hers Health by 9.5% during the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after purchasing an additional 29,471 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on HIMS shares. Truist Financial raised their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. UBS Group set a $23.00 target price on Hims & Hers Health in a research report on Friday, May 22nd. TD Cowen lifted their price target on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. dropped their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.